STEVE ELMS - 09 Feb 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: Director
Signature: /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact
Issuer symbol: ADMA
Transactions as of: 09 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2026, 21:00:09 UTC
Previous filing: 19 Nov 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
ELMS STEVE	Director	C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK	/s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact	11 Feb 2026	0001250195

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Award	$0	+10,690	+12%	$0.000000	98,020	09 Feb 2026	Direct	F1, F2
holding	ADMA	Common Stock						2,031,730	09 Feb 2026	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Stock Option (Right to Buy)	Award	$0	+17,730		$0.000000	17,730	09 Feb 2026	Common Stock	17,730	$16.37	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
F2	Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person.
F3	These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.
F4	These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.